The Medicines and Healthcare products Regulatory Agency (MHRA) in the USA has approved an expanded label for glatiramer acetate (Copaxone) injection to include the treatment of patients with clinical isolated syndrome (CIS) suggestive of multiple   more »

Bayer will launch a titration pack for patients with multiple sclerosis (MS) that is specially designed to make it easier for them to start Betaferon® / Betaseron (interferon beta-1b) therapy. From now on, the titration pack will be available in   more »

Taken just once a week, AVONEX is the multiple sclerosis (MS) treatment that people stay on longer. So when you're thinking about multiple sclerosis treatments, choose AVONEX. AVONEX empowers   more »

Biogen Idec, Elan's partner in the development and sale of Tysabri, is testing the efficacy of a malaria pill developed during the Vietnam war in treating progressive multifocal leukoencephalopathy (PML), the brain infection that has been tied to use of Tysabri, according to Al Sandrock, Biogen's head of neurology   more »

Biogen Idec Inc (BIIB.O: Quote, Profile, Research, Stock Buzz) said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the   more »

To determine the safety, effectiveness, and tolerability of natalizumab use in pediatric   more »

A drug used to treat multiple sclerosis might make some patients vulnerable to brain infection by reducing the number of immune cells there, researchers at UT Southwestern Medical Center have found. The findings also suggest that the drug, Natalizumab (Tysabri), might be safer and   more »

Glatiramer acetate decreases the chance of relapse in patients with multiple sclerosis (MS) and lowers medical costs compared with interferon beta-1b (IFN-B-1b), according to a retrospective analysis of data collected   more »

In this phase 2, randomized, blinded trial involving previously untreated, early, relapsing-remitting multiple sclerosis, we assigned 334 patients with scores of 3.0 or less on the Expanded Disability Status Scale and a disease duration of 3 years or less to receive   more »

Bayer HealthCare Pharmaceuticals Inc. is proud to announce that BETASERON (interferon beta-1b) is now available with a new 30-gauge needle, which is the thinnest needle in MS therapy. The new   more »

The different disease-modifying drugs available on the market for treatment of relapsing-remitting multiple sclerosis (MS) result in similar rates of disease relapse when examined over the long term, according   more »

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA | Quote | Chart | News | PowerRating) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be   more »

Mitoxantrone (mye-toe-ZAN-trone) belongs to the general group of medicines known as antineoplastics. It is used to treat some kinds of cancer. It is also used to treat some forms of multiple sclerosis (MS). This medicine    more »

FDA is informing health care professionals about additional recommendations for cardiac monitoring and reminding of the importance of monitoring cardiac function in patients with multiple sclerosis (MS) who are treated with mitoxantrone.   more »

The European Commission has approved Extavia® (interferon beta-1b) for the treatment of early and relapsing forms of multiple sclerosis (MS) - the first   more »